{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:35:23Z","timestamp":1792496123439,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed\/refractory (R\/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti\u2013PD-1 based salvage on outcomes for patients with R\/R cHL, we retrospectively reviewed 1280 patients with R\/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P&amp;lt; .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1\u2013based salvage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030151","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:18:05Z","timestamp":1765984685000},"page":"1125-1134","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["PD-1\u2013based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2625","authenticated-orcid":false,"given":"Sanjal H.","family":"Desai","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-8882","authenticated-orcid":false,"given":"Levi D.","family":"Pederson","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7751-8429","authenticated-orcid":false,"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-4495","authenticated-orcid":false,"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-6998","authenticated-orcid":false,"given":"Ayo S.","family":"Falade","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-0623","authenticated-orcid":false,"given":"Nuttavut","family":"Sumransub","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay She","family":"Ng","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7322","authenticated-orcid":false,"given":"Kelsey","family":"Baron","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-6975","authenticated-orcid":false,"given":"Shin Yeu","family":"Ong","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yoon","sequence":"additional","affiliation":[{"name":"8Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Iyengar","sequence":"additional","affiliation":[{"name":"9Division of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Micallef","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert","family":"Stuver","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"10Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[{"name":"10Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2026030511220991600_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026030511220991600_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10450","key":"2026030511220991600_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"suppl 1","key":"2026030511220991600_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2024-200992","article-title":"Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma [abstract]","volume":"144","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"2026030511220991600_bib5","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026030511220991600_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2024-204113","article-title":"A randomized phase 2 study incorporating nivolumab and brentuximab vedotin into radiation-free treatment of early stage classic Hodgkin lymphoma [abstract]","volume":"144","author":"LaCasce","year":"2024","journal-title":"Blood"},{"issue":"9323","key":"2026030511220991600_bib7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"8852","key":"2026030511220991600_bib8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"7","key":"2026030511220991600_bib9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2026030511220991600_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2026030511220991600_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"2026030511220991600_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","volume":"9","author":"Broccoli","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026030511220991600_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"2026030511220991600_bib14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"2026030511220991600_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2026030511220991600_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026030511220991600_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12916-024-03329-8","article-title":"Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial","volume":"22","author":"Liu","year":"2024","journal-title":"BMC Med"},{"issue":"8","key":"2026030511220991600_bib18","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2026030511220991600_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"28","key":"2026030511220991600_bib20","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026030511220991600_bib21","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"supp 1","key":"2026030511220991600_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2021-144610","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma [abstract]","volume":"138","author":"Lynch","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026030511220991600_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"22","key":"2026030511220991600_bib24","first-page":"2727","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","volume":"141","author":"Spinner","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026030511220991600_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.14245","article-title":"Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation","volume":"175","author":"Shah","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2026030511220991600_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026030511220991600_bib27","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"issue":"25","key":"2026030511220991600_bib28","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026030511220991600_bib29","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2026030511220991600_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.16756","article-title":"Checkpoint blockade treatment sensitises relapsed\/refractory non-Hodgkin lymphoma to subsequent therapy","volume":"191","author":"Carreau","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2026030511220991600_bib31","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/10\/1125\/2506822\/blood_bld-2025-030151-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/10\/1125\/2506822\/blood_bld-2025-030151-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:22:17Z","timestamp":1772727737000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/10\/1125\/557375\/PD-1-based-combinations-before-autologous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030151","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,5]]},"published":{"date-parts":[[2026,3,5]]}}}